ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Comparison of Oropharyngeal Candidiasis Outcomes in Renal Transplant Recipients Receiving Nystatin or No Antifungal Prophylaxis

T. Q. Ky, L. Cotiguala, L. Fitzgerald, K. McMurry, J. Park, S. Tischer

Pharmacy, University of Michigan, Michigan Medicine, Ann Arbor, MI

Meeting: 2020 American Transplant Congress

Abstract number: 65

Keywords: Efficacy, Fungal infection, Kidney transplantation, Post-operative complications

Session Information

Date: Saturday, May 30, 2020

Session Name: Antimicrobial & Diagnostic Stewardship in Transplantation

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:03pm-4:15pm

Location: Virtual

Related Abstracts
  • Incidence of Oropharyngeal and Esophageal Candidiasis in Adult Kidney Transplant Recipients Receiving Nystatin versus No Prophylaxis
  • Targeted Antifungal Prophylaxis in Liver Transplant Recipients: Two Year, Retrospective Cohort Analysis

*Purpose: Oropharyngeal candidiasis (OC) rate in the absence of antifungal prophylaxis has been reported as low as 7.4% after renal transplant. Due to perceived low rates of OC and unavailability of nystatin during a national shortage, our center began to withhold any type of antifungal prophylaxis after renal transplant. The objective of this study was to compare the incidence of OC in patients receiving no prophylaxis versus nystatin.

*Methods: This single-center retrospective chart review compared adult renal transplant recipients (RTRs) receiving either nystatin oral suspension 500,000 units four times daily for 30 days or no antifungal prophylaxis. Patients were transplanted between July 2018 and September 2019 and received maintenance immunosuppression of tacrolimus, mycophenolate with or without prednisone. Patients were excluded if they received systemic antifungal treatment for any indication other than OC or died within 3 months of transplant. The primary outcome was the incidence of OC within 3 months of transplant, with a non-inferiority margin of 15% and a power of 90%. Secondary outcomes included time to OC occurrence and severity of OC.

*Results: There were 149 RTRs who met inclusion criteria. Two groups were well matched for baseline characteristics. [Table 1] In the no prophylaxis group, 5 of 73 RTRs (6.8%) developed OC within 3 months post-transplant, compared to 4 of 76 RTRs (5.3%) in the nystatin group (p = 0.742). There was a difference of +1.6% (95% CI -6.2 to 9.4%) in OC rate in the no prophylaxis group. The median time to OC was 63 days (IQR 34 – 87) in the nystatin group and 12 days (IQR 5 – 14) in the no prophylaxis group (p = 0.086). Two of the 5 infected RTRs in the no prophylaxis group developed EGD-confirmed esophagitis compared to none in the nystatin prophylaxis group. All RTRs with OC achieved symptom resolution with fluconazole (n = 8) or nystatin (n = 1). Only 1 RTR in the no prophylaxis group required readmission due to thrush. [Table 2]

*Conclusions: In this single-center retrospective study, the absence of antifungal prophylaxis was non-inferior to 30-day nystatin prophylaxis at reducing the incidence of OC within 3 months post-transplant. Although not statistically significant, the median time to OC was shorter in the no prophylaxis group than in the nystatin group. All patients who developed OC, including the two RTRs with esophagitis in the no prophylaxis group, had resolution of infection with treatment. A larger randomized, controlled trial is needed to evaluate the absolute benefit of antifungal prophylaxis in RTRs.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ky TQ, Cotiguala L, Fitzgerald L, McMurry K, Park J, Tischer S. Comparison of Oropharyngeal Candidiasis Outcomes in Renal Transplant Recipients Receiving Nystatin or No Antifungal Prophylaxis [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-oropharyngeal-candidiasis-outcomes-in-renal-transplant-recipients-receiving-nystatin-or-no-antifungal-prophylaxis/. Accessed March 1, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Left-Sided Donor Nephrectomy Predisposes Living Kidney Donors to Latent Adrenal Insufficiency with Symptoms of Fatigue and Inferior Quality of Life.
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.